Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Tohen, M. Articles by Baker, R. W. Search for Related Content PubMed Citation Articles by Tohen, M. Articles by Baker, R. W. Bipolar Disorder Anticonvulsants Atypical Neuroleptics

Olanzapine Versus Divalproex Sodium for the Treatment of Acute Mania and Maintenance of Remission: A 47-Week Study

OBJECTIVE: Few double-blind trials have compared longer-term efficacy and safety of medications for bipolar disorder. The authors report a 47-week comparison of olanzapine and divalproex. METHOD: This 47-week, randomized, double-blind study compared flexibly dosed olanzapine (5–20 mg/day) to divalproex (500–2500 mg/day) for manic or mixed episodes of bipolar disorder (N=251). The only other psychoactive medication allowed was lorazepam for agitation. The primary efficacy instrument was the Young Mania Rating Scale; a priori protocol-defined threshold scores were 20 for inclusion, 12 for remission, and 15 for relapse. Analytical techniques included mixed model repeated-measures analysis of variance for change from baseline, Fisher’s exact test (two-tailed) for categorical comparisons, and Kaplan-Meier estimates of time to events of interest. RESULTS: Over 47 weeks, mean improvement in Young Mania Rating Scale score was significantly greater for the olanzapine group. Median time to symptomatic mania remission was significantly shorter for olanzapine, 14 days, than for divalproex, 62 days. There were no significant differences between treatments in the rates of symptomatic mania remission over the 47 weeks (56.8% and 45.5%, respectively) and subsequent relapse into mania or depression (42.3% and 56.5%). Treatment-emergent adverse events occurring significantly more frequently during olanzapine treatment were somnolence, dry mouth, increased appetite, weight gain, akathisia, and high alanine aminotransferase levels; those for divalproex were nausea and nervousness. CONCLUSIONS: In this 47-week study of acute bipolar mania, symptomatic remission occurred sooner and overall mania improvement was greater for olanzapine than for divalproex, but rates of bipolar relapse did not differ.

This article has been cited by other articles:

				M. Tohen, C. L. Bowden, A. B. Smulevich, R. Bergstrom, T. Quinlan, O. Osuntokun, W. V. Wang, H. S. Oliff, F. Martenyi, L. A. Kryzhanovskaya, et al. Olanzapine plus carbamazepine v. carbamazepine alone in treating manic episodes The British Journal of Psychiatry, February 1, 2008; 192(2): 135 - 143. [Abstract] [Full Text] [PDF]

				J. McKendrick, K.H. Cerri, A. LLoyd, A. D'AusiLio, S. Dando, and C. Chinn Cost effectiveness of olanzapine in prevention of affective episodes in bipolar disorder in the United Kingdom J Psychopharmacol, August 1, 2007; 21(6): 588 - 596. [Abstract] [PDF]

				C. A. Tamminga and J. M. Davis The Neuropharmacology of Psychosis Schizophr Bull, July 1, 2007; 33(4): 937 - 946. [Abstract] [Full Text] [PDF]

				W.S. Leslie, C.R. Hankey, and M.E.J. Lean Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review QJM, July 1, 2007; 100(7): 395 - 404. [Abstract] [Full Text] [PDF]

				G. S. Sachs Bipolar Disorder Clinical Synthesis: Where Does the Evidence Lead? Focus, January 1, 2007; 5(1): 3 - 13. [Abstract] [Full Text] [PDF]

				R. M. A. Hirschfeld Guideline Watch (November 2005): Practice Guideline for the Treatment of Patients with Bipolar Disorder, 2nd Edition Focus, January 1, 2007; 5(1): 34 - 39. [Abstract] [Full Text] [PDF]

				Bibliography BIPOLAR DISORDER Focus, January 1, 2007; 5(1): 40 - 43. [Full Text] [PDF]

				M. Gitlin Treatment-Resistant Bipolar Disorder Focus, January 1, 2007; 5(1): 49 - 63. [Abstract] [Full Text] [PDF]

				L. Citrome Maintenance treatment with olanzapine reduces relapse in people with bipolar I disorder who have responded to acute olanzapine treatment. Evid. Based Ment. Health, August 1, 2006; 9(3): 73 - 73. [Full Text] [PDF]

				S. N. Ghaemi, D. J. Hsu, M. E. Thase, S. R. Wisniewski, A. A. Nierenberg, S. Miyahara, and G. Sachs Pharmacological Treatment Patterns at Study Entry for the First 500 STEP-BD Participants Psychiatr Serv, May 1, 2006; 57(5): 660 - 665. [Abstract] [Full Text] [PDF]

				R. H. McAllister-Williams Relapse prevention in bipolar disorder: a critical review of current guidelines. J Psychopharmacol, March 1, 2006; 20(2 Suppl): 12 - 16. [Abstract] [PDF]

				A. H. Young and J. I. Newham Lithium in maintenance therapy for bipolar disorder. J Psychopharmacol, March 1, 2006; 20(2 Suppl): 17 - 22. [Abstract] [PDF]

				J. Cookson and B. Elliott The use of anticonvulsants in the aftermath of mania. J Psychopharmacol, March 1, 2006; 20(2_suppl): 23 - 30. [Abstract] [PDF]

				S. Dando and M. Tohen Olanzapine - relapse prevention following mania. J Psychopharmacol, March 1, 2006; 20(2 Suppl): 31 - 38. [Abstract] [PDF]

				J. S. E. Hellewell A review of the evidence for the use of antipsychotics in the maintenance treatment of bipolar disorders. J Psychopharmacol, March 1, 2006; 20(2 Suppl): 39 - 45. [Abstract] [PDF]

				M. Tohen, W. Greil, J. R. Calabrese, G. S. Sachs, L. N. Yatham, B. M. Oerlinghausen, A. Koukopoulos, G. B. Cassano, H. Grunze, R. W. Licht, et al. Olanzapine Versus Lithium in the Maintenance Treatment of Bipolar Disorder: A 12-Month, Randomized, Double-Blind, Controlled Clinical Trial Am J Psychiatry, July 1, 2005; 162(7): 1281 - 1290. [Abstract] [Full Text] [PDF]

				Drug treatments for bipolar disorder: 2 - Maintenance, prevention and special situations DTB, May 1, 2005; 43(5): 33 - 37. [Abstract] [Full Text] [PDF]

				I. M. Salloum, J. R. Cornelius, D. C. Daley, L. Kirisci, J. M. Himmelhoch, and M. E. Thase Efficacy of Valproate Maintenance in Patients With Bipolar Disorder and Alcoholism: A Double-blind Placebo-Controlled Study Arch Gen Psychiatry, January 1, 2005; 62(1): 37 - 45. [Abstract] [Full Text] [PDF]

				I. M. Anderson, P. M. Haddad, and I. Chaudhry Changes in Pharmacological treatment for Bipolar Disorder Over Time in Manchester: A Comparison with Lloyd et al. (2003) J Psychopharmacol, September 1, 2004; 18(3): 441 - 444. [PDF]

				P. Mackin, C. Fisher, and W. Broderick Sodium valproate or valproate semisodium? Psychiatr. Bull., July 1, 2004; 28(7): 264 - 264. [Full Text] [PDF]

				F. T. Lewis, E. Kass, and R. M. Klein An Overview of Primary Care Assessment and Management of Bipolar Disorder J Am Osteopath Assoc, June 1, 2004; 104(6_suppl): S2 - S8. [Abstract] [Full Text] [PDF]

				R. J. Baldessarini and L. Tondo Suicide Risk and Treatments for Patients With Bipolar Disorder JAMA, September 17, 2003; 290(11): 1517 - 1519. [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2003 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us